UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
2016, ISBN 9780809334728, xii, 295
Book
Journal of clinical oncology, ISSN 0732-183X, 09/2008, Volume 26, Issue 25, pp. 4092 - 4099
Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | Medical sciences | Tumors | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Docetaxel | Proportional Hazards Models | Lymphatic Metastasis | Breast Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Doxorubicin - administration & dosage | Index Medicus | Breast Cancer
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2006, Volume 354, Issue 3, pp. 270 - 282
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | General aspects | Medical sciences | Tumors | Receptors, Estrogen - metabolism | Signal Transduction | Humans | Risk Factors | Female | DNA Damage | Breast Neoplasms - chemically induced | Carcinogens - metabolism | Estrogens - adverse effects | Estrogens - metabolism | Breast Neoplasms - drug therapy | Women | Breast cancer | Health aspects | Risk factors | Estrogen | Hormone replacement therapy | Menopause | Estrogens | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 07/2018, Volume 379, Issue 2, pp. 122 - 137
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Breast Neoplasms - surgery | Follow-Up Studies | Neoplasm Recurrence, Local - prevention & control | Premenopause | Humans | Middle Aged | Kaplan-Meier Estimate | Breast Neoplasms - drug therapy | Young Adult | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Adult | Female | Androstadienes - therapeutic use | Receptor, ErbB-2 | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Women | Care and treatment | Usage | Hormone therapy | Analysis | Breast cancer | Health aspects | Medical research | Oncology | Tamoxifen | Cancer therapies | Survival | ErbB-2 protein | Studies | Design | Chemotherapy | Hospitals | Womens health | Aromatase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 55 - 65
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Predictive Value of Tests | Recurrence | United States - epidemiology | Breast Neoplasms - secondary | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Gene Expression Profiling | Receptors, Estrogen - analysis | Genetic Testing - methods | Cyclophosphamide - therapeutic use | Patient Selection | Fluorouracil - therapeutic use | Breast Neoplasms - chemistry | Clinical Trials, Phase III as Topic | Time Factors | Postmenopause | Adult | Female | Retrospective Studies | Risk Assessment | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Lymphatic Metastasis | Reverse Transcriptase Polymerase Chain Reaction | Breast Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Disease-Free Survival | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tamoxifen - therapeutic use | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Chemotherapy | Cyclophosphamide | Clinical trials | genomics | Breast cancer | Tamoxifen | Doxorubicin | Survival | Nodes | Post-menopause | Index Medicus
Journal Article
Nature genetics, ISSN 1061-4036, 12/2013, Volume 45, Issue 12, pp. 1415 - 1416
Life Sciences & Biomedicine | Genetics & Heredity | Science & Technology | Drug Resistance, Neoplasm - genetics | Animals | Estrogen Receptor alpha - genetics | Breast Neoplasms - pathology | Protein Interaction Domains and Motifs - genetics | Antineoplastic Agents, Hormonal - therapeutic use | Humans | Female | Mutation, Missense | Breast Neoplasms - drug therapy | Receptors | Breast cancer | Genetic aspects | Gene mutations | Identification and classification | Estrogen | Proteins | Studies | Clinical trials | Endocrine therapy | Ligands | Mutation | Drug dosages | Cancer therapies | Tumors
Journal Article
2009, 1. Aufl., ISBN 0813820812, 609
eBook
The New England journal of medicine, ISSN 0028-4793, 10/2005, Volume 353, Issue 16, pp. 1673 - 1684
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Biological and medical sciences | General aspects | Medical sciences | Tumors | Breast Neoplasms - surgery | Recurrence | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Antibodies, Monoclonal, Humanized | Doxorubicin - analogs & derivatives | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | Heart Diseases - chemically induced | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Proportional Hazards Models | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Breast Neoplasms - mortality | Receptor, ErbB-2 - analysis | Trastuzumab | Women | Breast cancer | Drug therapy | Health aspects | FDA approval | Radiation therapy | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 09/2011, Volume 29, Issue 25, pp. 3366 - 3373
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Antineoplastic agents | Combined treatments (chemotherapy of immunotherapy associated with an other treatment) | Pharmacology. Drug treatments | Tumors | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Carcinoma, Ductal, Breast - mortality | Carcinoma, Lobular - mortality | Young Adult | Antibodies, Monoclonal, Humanized | Carcinoma, Ductal, Breast - drug therapy | Time Factors | Adult | Female | Chemotherapy, Adjuvant | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Carcinoma, Ductal, Breast - surgery | Carcinoma, Lobular - surgery | Neoplasm Invasiveness | Survival Rate | Treatment Outcome | Combined Modality Therapy | Breast Neoplasms - drug therapy | Remission Induction | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Breast Neoplasms - mortality | Carcinoma, Lobular - drug therapy | Trastuzumab | Index Medicus | Bc6 | Original Reports | Bc5
Journal Article